SoftBank Vision Fund 2, a venture capital fund, led a $180m Series C financing round in Deep Genomics, an artificial intelligence therapeutics company. Additional investors include CPP Investments, Fidelity Management & Research Company, Alexandria Venture Investments, Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures. “This financing further validates the significant advances in our AI discovery platform and growth of our proprietary preclinical pipeline,” “It is rewarding to work with investors who recognize the long-term potential of our AI platform as we continue to identify novel targets and develop transformative medicines for patients,” Brendan Frey, Deep Genomics Founder & CEO.